

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST

**CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
EpiCept Corporation		05/27/2011	CORPORATION: DELAWARE
Maxim Pharmaceuticals, Inc.		05/27/2011	CORPORATION: DELAWARE
Cytovia, Inc.		05/27/2011	CORPORATION: DELAWARE

**RECEIVING PARTY DATA**

<b>Name:</b>	MidCap Funding III, LLC
<b>Street Address:</b>	7735 Old Georgetown Road
<b>Internal Address:</b>	Suite 400
<b>City:</b>	Bethesda
<b>State/Country:</b>	MARYLAND
<b>Postal Code:</b>	20814
<b>Entity Type:</b>	LIMITED LIABILITY COMPANY: DELAWARE

**PROPERTY NUMBERS Total: 4**

Property Type	Number	Word Mark
Registration Number:	2967403	CEPLENE
Serial Number:	85021009	CEPLENE
Registration Number:	3252103	VONTIV
Serial Number:	85009435	CROLIBULIN

**CORRESPONDENCE DATA**

Fax Number: (404)443-5697  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
 Phone: 404-443-5742  
 Email: lallen@mcguirewoods.com  
 Correspondent Name: Lizzie Garner, Esq.  
 Address Line 1: 1230 Peachtree Street, N.E.  
 Address Line 2: Suite 2100  
 Address Line 4: Atlanta, GEORGIA 30309

**OP \$1115.00 2967403**

**TRADEMARK**

ATTORNEY DOCKET NUMBER:	2061695-0002 (EPICEPT)
NAME OF SUBMITTER:	Latosha E. Allen
Signature:	/Latosha E. Allen/
Date:	05/31/2011

**Total Attachments: 36**

source=EpiCept - IP Security Agreement #page1.tif  
source=EpiCept - IP Security Agreement #page2.tif  
source=EpiCept - IP Security Agreement #page3.tif  
source=EpiCept - IP Security Agreement #page4.tif  
source=EpiCept - IP Security Agreement #page5.tif  
source=EpiCept - IP Security Agreement #page6.tif  
source=EpiCept - IP Security Agreement #page7.tif  
source=EpiCept - IP Security Agreement #page8.tif  
source=EpiCept - IP Security Agreement #page9.tif  
source=EpiCept - IP Security Agreement #page10.tif  
source=EpiCept - IP Security Agreement #page11.tif  
source=EpiCept - IP Security Agreement #page12.tif  
source=EpiCept - IP Security Agreement #page13.tif  
source=EpiCept - IP Security Agreement #page14.tif  
source=EpiCept - IP Security Agreement #page15.tif  
source=EpiCept - IP Security Agreement #page16.tif  
source=EpiCept - IP Security Agreement #page17.tif  
source=EpiCept - IP Security Agreement #page18.tif  
source=EpiCept - IP Security Agreement #page19.tif  
source=EpiCept - IP Security Agreement #page20.tif  
source=EpiCept - IP Security Agreement #page21.tif  
source=EpiCept - IP Security Agreement #page22.tif  
source=EpiCept - IP Security Agreement #page23.tif  
source=EpiCept - IP Security Agreement #page24.tif  
source=EpiCept - IP Security Agreement #page25.tif  
source=EpiCept - IP Security Agreement #page26.tif  
source=EpiCept - IP Security Agreement #page27.tif  
source=EpiCept - IP Security Agreement #page28.tif  
source=EpiCept - IP Security Agreement #page29.tif  
source=EpiCept - IP Security Agreement #page30.tif  
source=EpiCept - IP Security Agreement #page31.tif  
source=EpiCept - IP Security Agreement #page32.tif  
source=EpiCept - IP Security Agreement #page33.tif  
source=EpiCept - IP Security Agreement #page34.tif  
source=EpiCept - IP Security Agreement #page35.tif  
source=EpiCept - IP Security Agreement #page36.tif

**INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This Intellectual Property Security Agreement is entered into as of the 27<sup>th</sup> day of May, 2011 by and between MIDCAP FUNDING III, LLC, a Delaware limited liability company (“Agent”) and EPICEPT CORPORATION, MAXIM PHARMACEUTICALS INC., and CYTOVIA, INC. (collectively, the “Grantor”).

RECITALS

A. The Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the “Loans”) in the amounts and manner set forth in that certain Loan and Security Agreement by and between Agent, the Lenders and Grantor dated the Effective Date (as the same may be amended, modified or supplemented from time to time, the “Loan Agreement”; capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Agent, for the ratable benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its intellectual property (all of which shall collectively be called the “Intellectual Property Collateral”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “Copyrights”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the

same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “Patents”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “Trademarks”);

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “Mask Works”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

This security interest is granted in conjunction with the security interest granted to Agent, for the ratable benefit of the Lenders, under the Loan Agreement. The rights and remedies of Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Agent as a matter of law or equity. Each right, power and remedy of Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Agent, of any or all other rights, powers or remedies. Notwithstanding anything herein to the contrary, to the extent that there is any conflict between this Intellectual Property Security Agreement and the Loan Agreement, the Loan Agreement shall control.

*[Signature page follows.]*

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

Address of Grantor:

777 OLD SAW MILL RIVER ROAD  
TARRYTOWN, NY 10591  
Attn: ROBERT W. COOK

GRANTORS:

EPICEPT CORPORATION

By: Robert W. Cook

Title: SVP + CFO

MAXIM PHARMACEUTICALS, INC.

By: Robert W. Cook

Title: TREASURER

CYTOVIA, INC.

By: Robert W. Cook

Title: TREASURER

AGENT:

MIDCAP FUNDING III, LLC

Address of Agent:

7735 Old Georgetown Road, Suite 400  
Bethesda, Maryland 20814  
Attn: Portfolio Management- Life Sciences

By: \_\_\_\_\_

Title: \_\_\_\_\_

EPICEPT CORPORATION  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

TRADEMARK  
REEL: 004551 FRAME: 0033

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

Address of Grantor:

\_\_\_\_\_

Attn: \_\_\_\_\_

**GRANTORS:**

**EPICEPT CORPORATION**

By: \_\_\_\_\_

Title: \_\_\_\_\_

**MAXIM PHARMACEUTICALS, INC.**

By: \_\_\_\_\_

Title: \_\_\_\_\_

**CYTOVIA, INC.**

By: \_\_\_\_\_


Title: \_\_\_\_\_

Address of Agent:

7735 Old Georgetown Road, Suite 400  
Bethesda, Maryland 20814  
Attn: Portfolio Management- Life Sciences

**AGENT:**

**MIDCAP FUNDING III, LLC**

By:  \_\_\_\_\_

Title: Josh Groman  
Managing Director

**EXHIBIT A**

Copyrights

None.

**EXHIBIT B**

Patents

[See Attached]



## EpiCept Patent Portfolio (May 2011)

<u>SKGF. Ref.</u>	<u>Title</u>	<u>Country</u>	<u>Patent No./Appl. No.</u>	<u>Issue Date/File Date</u>	<u>Status</u>
1735.0010001	Dipeptide Caspase Inhibitors and the Use Thereof	USA	6,153,591 09/270,735	11/28/2000 3/16/1999	Granted.
1735.0030001	Novel Fluorescence Dyes and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases, Peptidases, Proteases, and Other Enzymes and the Use Thereof	USA	6,248,904 09/357,952	6/19/2001 7/21/1999	Granted.
1735.0030003	Novel Fluorescence Dyes and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases, Peptidases, Proteases, and Other Enzymes and the Use Thereof	USA	6,984,718 10/138,375	1/10/2006 5/6/2002	Granted.
1735.0280002	Dipeptide Apoptosis Inhibitors and the Use Thereof	USA	6,184,210 09/270,736	2/6/2001 3/16/1999	Granted.
1735.0280003	Dipeptide Apoptosis Inhibitors and the Use Thereof	USA	6,596,693 09/653,279	7/22/2003 8/31/2000	Granted.
1735.0280004	Dipeptide Apoptosis Inhibitors and the Use Thereof	USA	6,949,516 10/429,095	9/27/2005 5/5/2003	Granted.
1735.028AU01	Dipeptide Apoptosis Inhibitors and the Use Thereof	Australia	741203 97930/98	3/7/2002 10/9/1998	Granted.
1735.028CA01	Dipeptide Apoptosis Inhibitors and the Use Thereof	Canada	2,306,692 2,306,692	9/21/2010 10/9/1998	Granted.
1735.028CN01	Dipeptide Apoptosis Inhibitors and the Use Thereof	China	ZL98810022.3 98810022.3	2/18/2004 10/9/1998	Granted.
1735.028EP01	Dipeptide Apoptosis Inhibitors and the Use Thereof	EPC	98952166.1	10/9/1998	Pending.
1735.028JP01	Dipeptide Apoptosis Inhibitors and the Use Thereof	Japan	4439111 2000-515426	1/15/2010 10/9/1998	Granted.
1735.028KR01	Dipeptide Apoptosis Inhibitors and the Use Thereof	South Korea	10-0580333 10-2000-7003882	5/9/2006 10/9/1998	Granted.
1735.0290002	Novel Fluorogenic or Fluorescent Reporter Molecules and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases and Other Enzymes and the Use Thereof	USA	6,342,611 09/168,888	1/29/2002 10/9/1998	Granted.

1735.0290004	Novel Fluorogenic or Fluorescent Reporter Molecules and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases and Other Enzymes and the Use Thereof	USA	6,335,429 09/521,650	1/1/2002 3/8/2000	Granted.
1735.0290005	Novel Fluorogenic or Fluorescent Reporter Molecules and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases and Other Enzymes and the Use Thereof	USA	6,759,207 09/947,387	7/6/2004 9/7/2001	Granted.
1735.0290006	Novel Fluorogenic or Fluorescent Reporter Molecules and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases and Other Enzymes and the Use Thereof	USA	7,270,801 10/829,381	9/18/2007 4/22/2004	Granted.
1735.0320003	Gambogic Acid, Analogs and Derivatives as Activators of Caspases and Inducers of Apoptosis	USA	6,462,041 09/495,120	10/8/2002 2/1/2000	Granted.
1735.0320005	Gambogic Acid, Analogs and Derivatives as Activators of Caspases and Inducers of Apoptosis	USA	6,613,762 10/066,805	9/2/2003 2/6/2002	Granted.
1735.0330002	Substituted 2-Aminobenzamide Caspase Inhibitors and the Use Thereof	USA	6,620,782 09/527,225	9/16/2003 3/16/2000	Granted.
1735.0350002	Caspase Inhibitors and the Use Thereof	USA	6,355,618 09/545,565	3/12/2002 4/7/2000	Granted.
1735.0350003	Caspase Inhibitors and the Use Thereof	USA	6,716,818 09/987,417	4/6/2004 11/14/2001	Granted.
1735.0400002	Substituted Alpha-Hydroxy Acid Caspase Inhibitors and the Use Thereof	USA	6,495,522 09/649,810	12/17/2002 8/28/2000	Granted.
1735.0410002	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	6,906,203 09/705,840	6/14/2005 11/6/2000	Granted.
1735.0410003	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,507,762 11/072,499	3/24/2009 3/7/2005	Granted.
1735.041AU02	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Australia	12/31/4040 14619/01	10/6/2005 11/3/2000	Granted.
1735.041CA02	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Canada	1/16/8444 1/16/8444	3/29/2011 11/3/2000	Granted.
1735.041DE02	Substituted 4H-Chromene and Analogs as Activators of	Germany	1230232	2/25/2004	Granted.

	Caspases and Inducers of Apoptosis and the Use Thereof		976912.6	11/3/2000	
1735.041ES02	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Spain	4/3/5268 9/9/4574	2/25/2004 11/3/2000	Granted.
1735.041FR02	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	France	1230232 976912.6	2/25/2004 11/3/2000	Granted.
1735.041GB02	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Great Britain	1230232 976912.6	2/25/2004 11/3/2000	Granted.
1735.041IT02	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Italy	1230232 976912.6	2/25/2004 11/3/2000	Granted.
1735.0420002	1735.0420002 Caspase Inhibitors for the Treatment and Prevent Chemotherapy and Radiation Therapy Induced Cell Death	USA	6,566,338 09/685,689	5/20/2003 10/11/2000	Granted.
1735.0440001	Substituted Nicotinamide and Analogs as Activators of Caspases and Apoptosis and the Use Thereof	USA	6,794,397 09/769,420	9/21/2004 1/26/2001	Granted.
1735.0450001	Substituted 1,4-Thiazepene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	6,861,419 09/836,548	3/1/2005 4/18/2001	Granted.
1735.0470001	Method of Identifying Immunosuppressive Agents	USA	6,828,091 09/920,332	12/7/2004 8/2/2001	Granted.
1735.0500002	Substituted Indole-2-carboxylic Acid Benzylidenehydrazide and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	6,747,052 10/298,946	6/8/2004 11/19/2002	Granted.
1735.0520001	Substituted 2-Aryl-4-arylamino-pyrimidine and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	6,716,851 10/012,444	4/6/2004 12/12/2001	Granted.
1735.0520002	Substituted 2-Aryl-4-arylamino-pyrimidine and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,226,927 10/704,448	6/5/2007 11/10/2003	Granted.
1735.0540001	Multifluoro-substituted Chalcones and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,256,219 10/471,720	8/14/2007 10/16/2003	Granted.
1735.0560001	Substituted N'-(Arylcarbonyl)-benzhydrazides, N'-Benzylidenehydrazides and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	6,716,859 10/141,769	4/6/2004 5/10/2002	Granted.

1735.0560002	Substituted N'-(Arylcarbonyl)-benzhydrazides, N'-Benzylidenehydrazides and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,074,813 10/816,893	7/11/2006 4/5/2004	Granted.
1735.0600001	4-Substituted-1-(aryl(methylidene)thiosemicarbazide,4-substituted-1-(arylcarbonyl)thiosemicarbazide and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	6,794,400 10/158,827	9/21/2004 6/3/2002	Granted.
1735.0630001	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	USA	7,053,117 10/146,138	5/30/2006 5/16/2002	Granted.
1735.063AU11	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	Australia	2009200374	5/16/2002	Pending.
1735.063CA01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	Canada	2,447,010	05/16/2002	Pending. Allowed. Final fees to be paid by 05/22/2011.
1735.063CN01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	China	2812067.1 3/5/9599	12/2/2009 5/16/2002	Granted.
1735.063DE01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	Germany	1392683 7/12/9406	12/2/2009 5/16/2002	Granted.
1735.063EP01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	EPC	1392683 7/12/9406	12/2/2009 5/16/2002	Granted.
1735.063ES01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	Spain	1392683 2741704.7	12/2/2009 5/16/2002	Granted.
1735.063FR01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	France	1392683 2741704.7	12/2/2009 5/16/2002	Granted.
1735.063GB01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	United Kingdom	1392683 2741704.7	12/2/2009 5/16/2002	Granted.
1735.063IT01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	Italy	1/12/5713 7/12/9406	12/2/2009 5/16/2002	Granted.
1735.063JP01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	Japan	4593880 2002-589478	9/24/2010 5/16/2002	Granted.
1735.0640001	Substituted 3-Aryl-5-aryl-(1,2,4)-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,041,685 10/164,705	5/9/2006 6/10/2002	Granted.

1735.0640002	Substituted 3-Aryl-5-aryl-(1,2,4)-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,435,750 11/074,077	10/14/2008 3/8/2005	Granted.
1735.064AU01	Substituted 3-Aryl-5-aryl-(1,2,4)-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Australia	2002313633 2002313633	6/14/2007 6/10/2002	Granted.
1735.064CA01	Substituted 3-Aryl-5-aryl-(1,2,4)-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Canada	2,449,544	6/10/2002	Pending.
1735.064CN01	Substituted 3-Aryl-5-aryl-(1,2,4)-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	China	2813660.8	6/10/2002	Pending.
1735.064EP01	Substituted 3-Aryl-5-aryl-(1,2,4)-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	EPC	2753336.3	6/10/2002	Pending.
1735.064ZA01	Substituted 3-Aryl-5-aryl-(1,2,4)-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	South Africa	2003/9309 2003/9309	2/23/2005 6/10/2002	Granted.
1735.0650001	7,8-Fused 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	6,858,607 10/146,139	2/22/2005 5/16/2002	Granted.
1735.0660001	Substituted Coumarins and Quinolines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,015,328 10/146,136	3/21/2006 5/16/2002	Granted.
1735.0660002	Substituted Coumarins and Quinolines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,235,674 10/989,057	6/26/2007 11/16/2004	Granted.
1735.0750001	Substituted 4H-Chromenes, 2H-Chromenes, Chromans and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,476,741 10/514,426	1/13/2009 11/16/2004	Granted.
1735.0770001	Substituted 4-Aryl-4H-pyrrolo[2,3-h]chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,528,164 10/514,427	05/105/2009 11/16/2004	Granted.
1735.0780002	Derivatives of Gambogic Acid and Analogs as Activators of Caspases and Inducers of Apoptosis	USA	7,176,234 10/609,670	2/13/2007 7/10/2003	Granted.
1735.078AU02	Derivatives of Gambogic Acid and Analogs as	Australia	2003267977	09/102/2010	Granted.

	Activators of Caspases and Inducers of Apoptosis		2003267977		710112003
1735.078CN02	Derivatives of Gambogic Acid and Analogs as Activators of Caspases and Inducers of Apoptosis	China	3815628.8 3815628.8	09108/2010	Granted. 710112003
1735.0810001	Substituted l-Benzoyl-3-cyano-pyrrolo[1,2-a]quinolines and Analogs as Activators of Caspases and Inducers of Apoptosis	USA	7,135,480 101,733,229	11/14/2006	Granted. 12/12/2003
1735.0820001	3,5-Disubstituted-[1,2,4]-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,144,876 101,737,865	12105/2006	Granted. 12/18/2003
1735.0820002	3,5-Disubstituted-[1,2,4]-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,317,029 111,593,030	01108/2008 11106/2006	Granted.
1735.082AU01	3,5-Disubstituted-[1,2,4]-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Australia	2003303373 2003303373		5/27/2010 Granted. 12/18/2003
1735.082CNO1	3,5-Disubstituted-[1,2,4]-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	China	2.0038E+11 2.0038E+11		1/30/2008 Granted. 12/18/2003
1735.082EPO1	3,5-Disubstituted-[1,2,4]-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	EPC	3808469.5	12118/2003	Pending. Renewal fee not paid for 12/31/2010; deadline 06/30/2011.
1735.0840002	Methods of Treating Diseases Responsive to Induction of Apoptosis and Screening Assays	USA	7,592,143 10/826,909		9/22/2009 Granted. 4/19/2004
1735.088001	Protease Inhibitors for Corona virus and Sars-Co V and the Use Thereof	USA	7,504,382 10/839,753		3/17/2009 Granted. 05106/2004
1735.088CN06	Protease Inhibitors for Corona virus and Sars-Co V and the Use Thereof	China	2.0048E+11 2.0048E+11	07102/2008 05104/2004	Granted.
1735.0940001	Derivatives of Gambogic Acid and Analogs as Activators of Caspases and Inducers of Apoptosis	USA	7,622,497 10/580,263		11/24/2009 Granted. 5/25/2006
1735.1040001	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and the Use Thereof	USA	11/822,535	07106/2007	Pending. Allowed. Issue Fee due 05/23/2011.
1735.104AU01	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and	Australia	2007271743	07106/2007	Pending.

the Use Thereof

1735.104CAO 1	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and the Use Thereof	Canada	2,656,706	07106/2007	Pending.
1735.104CNOI	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and the Use Thereof	China	2.0078E+11	07106/2007	Pending.
1735.104EPOI	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and the Use Thereof	EPC	7810283.7	07106/2007	Pending.
1735.104JPO 1	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and the Use Thereof	Japan	2009-518401	07106/2007	Pending.
1735.1050002	3-Aryl-6-aryl-7 H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	111,879,517	07118/2007	Pending.
1735.105CA02	3-Aryl-6-aryl-7 H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Canada	2,657,931	07118/2007	Pending.
1735.105CN02	3-Aryl-6-aryl-7 H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	China	TBA	07118/2007	Pending.
1735.105EP02	3-Aryl-6-aryl-7 H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	EPC	7796912.9	07118/2007	Pending.
1735.105JP02	3-Aryl-6-aryl-7 H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Japan	2009-520810	07118/2007	Pending.
1735.1080001	3-aryl-6-aryl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and Related Compounds as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,732,468 111,984,296	06108/2010 11/15/2007	Granted.

Patent Status Report by Client

Tuesday, April 26, 2011

Client: MAXIM EpiCept Corporation

Client Code/SubCase	Case Type	Status	App Number	App Date	Next Action(s)	Due Date(s)
		Client/Referenc	Pat Number	Iss Date		
MAXIM.010CPI/	CIP	Issued	07/843052		2-Mar-92	
<i>Country:</i>	United States of America		5348739	20-Sep-94		
<i>Attorneys:</i>	MKD - Billing					
<i>Title:</i>	COMBINED ANTI-TUMOR THERAPY WITH INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS					
MAXIM.010VAT/	EPC	Issued		90914257.2	19-Sep-90	
<i>Country:</i>	Austria		493468	17-Apr-96		
<i>Attorneys:</i>	MKD - Billing					
<i>Title:</i>	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS					
MAXIM.010VAU/	ORD	Issued		64191/90	19-Sep-90	
<i>Country:</i>	Australia		640954	25-Jan-94		
<i>Attorneys:</i>	amb - IPS; MKD - Billing					
<i>Title:</i>	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS					
MAXIM.010VBE/	EPC	Issued		90914257.2	19-Sep-90	
<i>Country:</i>	Belgium		493468	17-Apr-96		
<i>Attorneys:</i>	MKD - Billing					
<i>Title:</i>	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS					
MAXIM.010VCA/	ORD	Issued		2066728	19-Sep-90	
<i>Country:</i>	Canada		2066728	25-Dec-01		
<i>Attorneys:</i>	amb - IPS; MKD - Billing					
<i>Title:</i>	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS					
MAXIM.010VCH/	EPC	Issued		90914257.2	19-Sep-90	
<i>Country:</i>	Switzerland		493468	17-Apr-96		
<i>Attorneys:</i>	MKD - Billing					
<i>Title:</i>	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS					
MAXIM.010VDE/	EPC	Issued		90914257.2	19-Sep-90	
<i>Country:</i>	Germany		493468	17-Apr-96		
<i>Attorneys:</i>	MKD - Billing					
<i>Title:</i>	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS					
MAXIM.010VDK/	EPC	Issued		90914257.2	19-Sep-90	
<i>Country:</i>	Denmark		493468	17-Apr-96		
<i>Attorneys:</i>	MKD - Billing					
<i>Title:</i>	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS					
MAXIM.010VEP/	ORD	Issued		90914257.2	19-Sep-90	
<i>Country:</i>	European Patent Convention		493468	17-Apr-96		
<i>Attorneys:</i>	amb - IPS; MKD - Billing					
<i>Title:</i>	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS					



MAXIM.010VES/	EPC	Issued	90914257.2	19-Sep-90
<i>Country:</i>	Spain	493468	17-Apr-96	
<i>Attorneys:</i>	MKD - Billing			
<i>Title:</i>	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS			
MAXIM.010VFR/	EPC	Issued	90914257.2	19-Sep-90
<i>Country:</i>	France	493468	17-Apr-96	
<i>Attorneys:</i>	MKD - Billing			
<i>Title:</i>	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS			
MAXIM.010VGB/	EPC	Issued	90914257.2	19-Sep-90
<i>Country:</i>	United Kingdom	493468	17-Apr-96	
<i>Attorneys:</i>	MKD - Billing			
<i>Title:</i>	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS			
MAXIM.010VII/	EPC	Issued	90914257.2	19-Sep-90
<i>Country:</i>	Italy	493468	17-Apr-96	
<i>Attorneys:</i>	MKD - Billing			
<i>Title:</i>	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS			
MAXIM.010VJP/	ORD	Issued	513349/1990	19-Sep-90
<i>Country:</i>	Japan	2845622	30-Oct-98	
<i>Attorneys:</i>	amb - IPS; MKD - Billing			
<i>Title:</i>	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS			
MAXIM.010VKR/	ORD	Issued	92-700628	19-Mar-92
<i>Country:</i>	Korea, Republic of	195392	11-Feb-99	
<i>Attorneys:</i>	amb - IPS; MKD - Billing			
<i>Title:</i>	A PHARMACEUTICAL PREPARATION OR SYSTEM, AND USE THEREOF FOR INHIBITING TUMOR GROWTH AND THE METASTASES OF (CONTINUED)			
MAXIM.010VLU/	EPC	Issued	90914257.2	19-Sep-90
<i>Country:</i>	Liechtenstein	493468	17-Apr-96	
<i>Attorneys:</i>	MKD - Billing			
<i>Title:</i>	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS			
MAXIM.010VLU/	EPC	Issued	90914257.2	19-Sep-90
<i>Country:</i>	Luxembourg	493468	17-Apr-96	
<i>Attorneys:</i>	MKD - Billing			
<i>Title:</i>	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS			
MAXIM.010VNL/	EPC	Issued	90914257.2	19-Sep-90
<i>Country:</i>	Netherlands	493468	17-Apr-96	
<i>Attorneys:</i>	MKD - Billing			
<i>Title:</i>	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS			
MAXIM.010VSE/	EPC	Issued	90914257.2	19-Sep-90
<i>Country:</i>	Sweden	493468	17-Apr-96	

<i>Attorneys:</i>	MKD - Billing				
<i>Title:</i>	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-RECEPTOR AGONISTS				
MAXIM.026C1/	CON	Issued	08/681108		22-Jul-96 11 1/2 YR L/C 6-Jun-11
<i>Country:</i>	United States of America		6071509	6-Jun-00 Tax 11.5	6-Dec-11
<i>Attorneys:</i>	MKD - Billing		11.5 GRACE PF	6-Jun-12	
<i>Title:</i>	ENHANCED ACTIVATION OF NATURAL KILLER CELLS USING AN NK CELL ACTIVATOR & A HYDROGEN PEROXIDE SCAVENGER OR INHIBITOR				
MAXIM.026C2/	CON	Issued	09/516641		1-Mar-00 LC re 11.5 M/Fee Due 23-Apr-13
<i>Country:</i>	United States of America		6375946	23-Apr-02 Tax 11.5	23-Oct-13
<i>Attorneys:</i>	MKD - Billing		11.5 M/Fee Due	23-Oct-13	
<i>Title:</i>	ENHANCED ACTIVATION OF NATURAL KILLER CELLS USING AN N 11.5 M/Fee Gra 23-Apr-14				
HYDROGEN PEROXIDE SCAVENGER OR INHIBITOR					
MAXIM.031APC/	ORD	Issued	08/374787		8-May-95
<i>Country:</i>	United States of America		5728378	17-Mar-98	
<i>Attorneys:</i>	MKD - Billing				
<i>Title:</i>	PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK-CELLS), SAID PREPARATION CONTAINING INTERFERON-ALPHA				
MAXIM.031C2/	CON	Issued	09/465432		21-Dec-99 11 1/2 YR LC RE M/FEE DUE 5-Dec-11
<i>Country:</i>	United States of America		6155266	5-Dec-00 Tax 11.5	5-Jun-12
<i>Attorneys:</i>	MKD - Billing		11 1/2 YR M/FE	5-Dec-12	
<i>Title:</i>	METHOD FOR TREATMENT OF CANCER AND INFECTIOUS DISEASE				
MAXIM.031C3/	CON	Issued	09/574874		19-May-00 11 1/2 YR LC RE M/FEE DUE 23-Oct-12
<i>Country:</i>	United States of America		6305380	23-Oct-01 Tax 11.5	23-Apr-13
<i>Attorneys:</i>	MKD - Billing		11 1/2 YR M/FE	23-Oct-13	
<i>Title:</i>	METHOD FOR TREATMENT OF CANCER AND INFECTIOUS DISEASE				
MAXIM.031QCA/	ORD	Issued		2136952	3-Jun-93
<i>Country:</i>	Canada		2136952	9-Aug-05	
<i>Attorneys:</i>	amb - IPS; MKD - Billing				
<i>Title:</i>	PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK CELLS), SAID PREPARATION CONTAINING INTERFERON-A AND HISTAMINE, SEROTONIN, AMINES OR SUBSTANCES WITH CORRESPONDING RECEPTOR ACTIVITY				
MAXIM.049CP1/	CIP	Issued	08/767338		16-Dec-96 11 1/2 YR LC RE M/FEE DUE 24-Apr-12
<i>Country:</i>	United States of America		6221893	24-Apr-01 Tax 11.5	24-Oct-12
<i>Attorneys:</i>	MKD - Billing		11 1/2 YR M/FE	24-Apr-13	
<i>Title:</i>	ADMINISTRATION OF HISTAMINE FOR THERAPEUTIC PURPOSES				
MAXIM.058A/	ORD	Issued	09/226226		6-Jan-99 LC re 11.5 M/Fee Due 24-Dec-13
<i>Country:</i>	United States of America		6498181	24-Dec-02 11.5 M/Fee Due	24-Jun-14
<i>Attorneys:</i>	MKD - Billing		11.5 M/Fee Gra	24-Dec-14	
<i>Title:</i>	SYNERGISTIC TUMORCIDAL RESPONSE INDUCED BY HISTAMINE				
MAXIM.066A/	ORD	Issued	09/227455		8-Jan-99 11 1/2 YR LC RE M/FEE DUE 5-Jun-12
<i>Country:</i>	United States of America		6242473	5-Jun-01 Tax 11.5	5-Dec-12
<i>Attorneys:</i>	CTS - Working; MKD - Billing		11 1/2 YR M/FE	5-Jun-13	
<i>Title:</i>	TREATMENT AND PREVENTION OF REACTIVE OXYGEN METABOLITE-MEDIATED CELLULAR DAMAGE				
MAXIM.066C1/	CON	Issued	09/707343		6-Nov-00 LC re 11.5 M/Fee Due 8-Oct-13
<i>Country:</i>	United States of America		6462067	8-Oct-02 Tax 11.5	8-Apr-14
<i>Attorneys:</i>	CTS - Working; MKD - Billing		11.5 M/Fee Due	8-Apr-14	

<i>Title:</i>	TREATMENT AND PREVENTION OF REACTIVE OXYGEN METABOLI	11.5 M/Fee Gra	8-Oct-14	
MAXIM.066DV1/	DIV	Issued 09/833896		12-Apr-01 LC re 11.5 M/Fee Due 18-Jun-13
<i>Country:</i>	United States of America	6407133	18-Jun-02 11.5 M/Fee Due	18-Dec-13
<i>Attorneys:</i>	CTS - Working; MKD - Billing	11.5 M/Fee Gra	18-Jun-14	
<i>Title:</i>	TREATMENT AND PREVENTION OF REACTIVE OXYGEN METABOLITE- MEDIATED CELLULAR DAMAGE			
MAXIM.066DV2/	DIV	Issued 10/171018		11-Jun-02 FT LC re 7.5 M/Fee Due 4-Sep-11
<i>Country:</i>	United States of America	6730692	4-May-04 Tax 7.5	4-Nov-11
<i>Attorneys:</i>	CTS - Working; MKD - Billing	7.5 M/Fee Gra	4-May-12	
<i>Title:</i>	TREATMENT AND PREVENTION OF REACTIVE OXYGEN METABOLI LC re 11.5 M/Fee Due		4-May-15	
			4-Sep-15	
			4-Nov-15	
			4-May-16	
MAXIM.067A/	ORD	Issued 09/467652		20-Dec-99 LC re 11.5 M/Fee Due 11-Jun-13
<i>Country:</i>	United States of America	6403806	11-Jun-02 11.5 M/Fee Due	11-Dec-13
<i>Attorneys:</i>	CTS - Working; MKD - Billing	11.5 M/Fee Gra	11-Jun-14	
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067C1/	CON	Issued 09/974469		9-Oct-01 LC re 11.5 M/Fee Due 4-Mar-14
<i>Country:</i>	United States of America	6528654	4-Mar-03 Tax 11.5	4-Sep-14
<i>Attorneys:</i>	CTS - Working; MKD - Billing	11.5 M/Fee Due	4-Sep-14	
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	11.5 M/Fee Gra	4-Mar-15	
MAXIM.067C2/	CON	Issued 10/364810		10-Feb-03 LC re 11.5 M/Fee Due 16-Sep-14
<i>Country:</i>	United States of America	6620942	16-Sep-03 Tax 11.5	16-Mar-15
<i>Attorneys:</i>	CTS - Working; MKD - Billing	11.5 M/Fee Due	16-Mar-15	
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	11.5 M/Fee Gra	16-Sep-15	
MAXIM.067VAT/	EPC	Issued 99968148.9		20-Dec-99
<i>Country:</i>	Austria	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VAU/	ORD	Issued 24825700		20-Dec-99
<i>Country:</i>	Australia	763523	6-Nov-03	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VBE/	EPC	Issued 99968148.9		20-Dec-99
<i>Country:</i>	Belgium	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VCA/	ORD	Issued 2356871		20-Dec-99
<i>Country:</i>	Canada	2356871	14-Sep-10	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VCH/	EPC	Issued 99968148.9		20-Dec-99
<i>Country:</i>	Switzerland	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VCN/	ORD	Issued 99814906.3		20-Dec-99
<i>Country:</i>	China (People's Republic)	ZL99814906.3	30-Jun-04	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			

<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VCY/	EPC	Issued	99968148.9	20-Dec-99
<i>Country:</i>	Cyprus, Republic of	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VDE/	EPC	Issued	99968148.9	20-Dec-99
<i>Country:</i>	Germany	69939027.3-08	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VDK/	EPC	Issued	99968148.9	20-Dec-99
<i>Country:</i>	Denmark	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VEP/	ORD	Issued	99968148.9	20-Dec-99
<i>Country:</i>	European Patent Convention	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VES/	EPC	Issued	99968148.9	20-Dec-99
<i>Country:</i>	Spain	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VEU/	EPC	Issued	99968148.9	20-Dec-99
<i>Country:</i>	Finland	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VFR/	EPC	Issued	99968148.9	20-Dec-99
<i>Country:</i>	France	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VGB/	EPC	Issued	99968148.9	20-Dec-99
<i>Country:</i>	United Kingdom	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VGR/	EPC	Issued	99968148.9	20-Dec-99
<i>Country:</i>	Greece	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VHK/	ORD	Issued	2102715.8	20-Dec-99
<i>Country:</i>	Hong Kong	HK1040998	24-Apr-09	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VIE/	EPC	Issued	99968148.9	20-Dec-99
<i>Country:</i>	Ireland	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VIL/	ORD	Issued	143570	20-Dec-99
<i>Country:</i>	Israel	143570	21-Nov-06	

<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VIN/	ORD	Issued	IN/PCT/2001/00601	20-Dec-99
<i>Country:</i>	India	205849	13-Apr-07	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VIT/	EPC	Issued	99968148.9	20-Dec-99
<i>Country:</i>	Italy	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VIP/	ORD	Issued	2000-591009	20-Dec-99
<i>Country:</i>	Japan	4139082	13-Jun-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VKR/	ORD	Pending	10-2001-7007847	20-Dec-99
<i>Country:</i>	Korea, Republic of			
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VLU/	EPC	Issued	99968148.9	20-Dec-99
<i>Country:</i>	Luxembourg	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VMC/	EPC	Issued	99968148.9	20-Dec-99
<i>Country:</i>	Monaco	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VNL/	EPC	Issued	99968148.9	20-Dec-99
<i>Country:</i>	Netherlands	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VNZ/	ORD	Issued	512935	20-Dec-99
<i>Country:</i>	New Zealand	512935	8-Dec-03	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VPT/	EPC	Issued	99968148.9	20-Dec-99
<i>Country:</i>	Portugal	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VSE/	EPC	Issued	99968148.9	20-Dec-99
<i>Country:</i>	Sweden	1140857	2-Jul-08	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VTW/	ORD	Issued	88122820	23-Dec-99
<i>Country:</i>	Taiwan	I243166	11-Nov-05	
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing			
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE			
MAXIM.067VZA/	ORD	Issued	2001/4552	20-Dec-99

<i>Country:</i>	South Africa	2001/4552	27-Mar-02		
<i>Attorneys:</i>	amb - IPS; CTS - Working; MKD - Billing				
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE				
MAXIM.073A/	ORD	Issued	09/227801	8-Jan-99	11 1/2 YR LC RE M/FEE DUE 7-Aug-12
<i>Country:</i>	United States of America	6270781	7-Aug-01	Tax 11.5	7-Feb-13
<i>Attorneys:</i>	MKD - Billing	11 1/2 YR M/FE	7-Aug-13		
<i>Title:</i>	METHODS AND COMPOSITIONS FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING REACTIVE OXYGEN METABOLITE PRODUCTION OR RELEASE INHIBITORS				
MAXIM.073DV/	DIV	Issued	09/765929	19-Jan-01	11 1/2 YR LC RE M/FEE DUE 26-Feb-13
<i>Country:</i>	United States of America	6350785	26-Feb-02	Tax 11.5	26-Aug-13
<i>Attorneys:</i>	MKD - Billing	11 1/2 YR M/FE	26-Feb-14		
<i>Title:</i>	METHODS AND COMPOSITIONS FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING REACTIVE OXYGEN METABOLITE PRODUCTION OR RELEASE INHIBITORS				
MAXIM.073QNZ/	ORD	Issued	513272	7-Jan-00	
<i>Country:</i>	New Zealand	513272	29-Mar-04		
<i>Attorneys:</i>	amb - IPS; MKD - Billing				
<i>Title:</i>	METHODS AND COMPOSITIONS FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING REACTIVE OXYGEN METABOLITE PRODUCTION OR RELEASE INHIBITORS				
MAXIM.078VAU/	ORD	Issued	200061044	14-Jul-00	
<i>Country:</i>	Australia	779215	19-May-05		
<i>Attorneys:</i>	amb - IPS; MKD - Billing				
<i>Title:</i>	USE OF DIPHENYLIONODONIUM FOR THE ACTIVATION AND PROTECTION OF CYTOTOXIC				
MAXIM.085DV/	DIV	Issued	10/160745	30-May-02	LC re 7.5 M/Fee Due 14-Sep-11
<i>Country:</i>	United States of America	6790440	14-Sep-04	FU LC re 7.5 M/Fee Due	14-Jan-12
<i>Attorneys:</i>	MKD - Billing	Tax 7.5	14-Mar-12		
<i>Title:</i>	METHODS AND COMPOSITIONS FOR PROMOTING THE MATURATION 7.5 M/Fee Grace				
LC re 11.5 M/Fee Due			14-Sep-15		
FU LC re 11.5 M/Fee Due			14-Jan-16		
Tax 11.5			14-Mar-16		
11.5 M/Fee Grace Period			14-Sep-16		
MAXIM.085DV3/	DIV	Issued	10/160360	30-May-02	LC re 7.5 M/Fee Due 17-May-12
<i>Country:</i>	United States of America	6893633	17-May-05	FU LC re 7.5 M/Fee Due	17-Sep-12
<i>Attorneys:</i>	MKD - Billing	Tax 7.5	17-Nov-12		
<i>Title:</i>	METHODS AND COMPOSITIONS FOR PROMOTING THE MATURATION 7.5 M/Fee Grace				
LC re 11.5 M/Fee Due			17-May-16		
FU LC re 11.5 M/Fee Due			17-Sep-16		
Tax 11.5			17-Nov-16		
11.5 M/Fee Grace Period			17-May-17		
MAXIM.085DV4/	DIV	Issued	10/160368	30-May-02	LC re 7.5 M/Fee Due 23-Nov-11
<i>Country:</i>	United States of America	6821510	23-Nov-04	FU LC re 7.5 M/Fee Due	23-Mar-12
<i>Attorneys:</i>	MKD - Billing	Tax 7.5	23-May-12		
<i>Title:</i>	METHODS AND COMPOSITIONS FOR PROMOTING THE MATURATION 7.5 M/Fee Grace				
LC re 11.5 M/Fee Due			23-Nov-15		
FU LC re 11.5 M/Fee Due			23-Mar-16		
Tax 11.5			23-May-16		
11.5 M/Fee Grace Period			23-Nov-16		
MAXIM.217VPC/	ORD	Published	PCT/US2010/030604	9-Apr-10	File Refs in All IL Applicatio 18-May-11

<i>Country:</i>	Patent Cooperation Treaty	IDS in US Appli	18-May-11
<i>Attorneys:</i>	amb - IPS; MKD - Billing; MZP - Working	File Resp w/Den	18-May-11
<i>Title:</i>	COMPOSITION AND USE OF N-ALPHA-METHYLHISTAMINE DIHYDR LC 30 Month N		16-Jul-11
OXYGEN RADICAL FORMATION	FU LC re 30 Month NP / IPS	16-Aug-11	
Prepare FFNP Memo / Asst		16-Sep-11	
NP w/out Late Fee / ATTY		18-Sep-11	
NP w/\$100 Late Fee / ATTY		2-Oct-11	
NP w/\$300 Late Fee / ATTY		9-Oct-11	
File Nat'l Phase in US? / ATTY		16-Oct-11	
NP 30 Month Date FINAL / IPS		16-Oct-11	
NP 31 Month Date FINAL / IPS		16-Nov-11	
MAXIM.26D1F1/	FW	Issued 08/932406	17-Sep-97 11 1/2 YR L/C 16-May-11
<i>Country:</i>	United States of America	6063373	16-May-00 Tax 11.5 16-Nov-11
<i>Attorneys:</i>	MKD - Billing	11.5 GRACE PF	16-May-12
<i>Title:</i>	ENHANCED ACTIVATION OF NK CELLS USING AN NK CELL ACTIVATOR AND A HYDROGEN PEROXIDE		
SCAVENGER OR INHIBITOR			
MAXIM.26D1F1C1/	CON	Issued 09/516738	1-Mar-00 11 1/2 YR LC REM/FEE DUE 12-Jun-12
<i>Country:</i>	United States of America	6245563	12-Jun-01 Tax 11.5 12-Dec-12
<i>Attorneys:</i>	MKD - Billing	11 1/2 YR M/FE	12-Jun-13
<i>Title:</i>	ENHANCED ACTIVATION OF NATURAL KILLER CELLS USING AN NK CELL ACTIVATOR AND A		
HYDROGEN PEROXIDE SCAVENGER OR INHIBITOR			
MAXIM.31C1/	CON	Issued 09/033110	2-Mar-98 Tax 11.5 21-Jun-11
<i>Country:</i>	United States of America	6003516	21-Dec-99 Tax 11.5 21-Jun-11
<i>Attorneys:</i>	MKD - Billing		
<i>Title:</i>	METHOD FOR TREATMENT OF CANCER AND INFECTIOUS DISEASE		
MAXIM.49CPCP/	CIP	Issued 08/969384	13-Nov-97 11 1/2 YR L/C 6-Jun-11
<i>Country:</i>	United States of America	6071942	6-Jun-00 Tax 11.5 6-Dec-11
<i>Attorneys:</i>	MKD - Billing	11.5 GRACE PF	6-Jun-12
<i>Title:</i>	ELEVATION OF CIRCULATING BLOOD HISTAMINE LEVELS		

# Jones Day Patent Report (No Actions:No 502s)

April 26, 2011

Docket No. CAM No.	Client Owner	Patent Title	Inventors	App# App Date	Pat # Pat Date
010071-0005-007	EPICEPT CORPORATION	INTRADERMAL PENETRATION AGENTS FOR TOPICAL LOCAL ANESTHETICS USING A PATCH	WILFRIED FISCHER KATHARINASTOEGER PETRA FISBER	2001245449	2001245449
301717-007004	EPICEPT, INC.			6-Mar-01	5-Jul-07
Australia Registered					
	Attorneys:		ILENE B. TANNEN PETER G. THURLOW		
010071-0005-008	EPICEPT CORPORATION	INTRADERMAL PENETRATION AGENTS FOR TOPICAL LOCAL ANESTHETICS USING A PATCH	WILFRIED FISCHER KATHARINASTOEGER PETRA FISBER	521470	521470
301717-008004	EPICEPT, INC.			March 6, 2001	11-Nov-04
New Zealand Registered					
	Attorneys:		ILENE B. TANNEN PETER G. THURLOW		
010071-0005-009	EPICEPT CORPORATION	INTRADERMAL PENETRATION AGENTS FOR TOPICAL LOCAL ANESTHETICS USING A PATCH	WILFRIED FISCHER KATHARINASTOEGER PETRA FISBER	20021008828	237220
301717-009004	EPICEPT, INC.			6-Mar-01	26-May-06
Mexico Registered					
	Attorneys:		ILENE B. TANNEN PETER G. THURLOW		



010071-0005-012 EPICEPT CORPORATION INTRADERMAL  
PENETRATION  
AGENTS FOR WILFRIED FISCHER  
TOPICAL KATHARINASTOEGER 13-566701  
LOCAL PETRA ffr/BER  
ANESTHETICS  
USING A  
PATCH

301717-012004 EPICEPT, INC. 6-Mar-01

Japan  
Pending

Attorneys: ILENE B. TANNEN PETER G. THURLOW

---

010071-0005-056 EPICEPT CORPORATION INTRADERMAL  
PENETRATION  
AGENTS FOR WILFRIED FISCHER  
TOPICAL KATHARINASTOEGER 2/002:01640 209506  
LOCAL PETRA ffr/BER  
ANESTHETICS  
USING A  
PATCH

301717-056004 EPICEPT, INC. 6-Mar-01 4-Sep-07

India  
Registered

Attorneys: ILENE B. TANNEN PETER G. THURLOW

---

010071-0005-117 EPICEPT CORPORATION INTRADERMAL  
PENETRATION  
AGENTS FOR WILFRIED FISCHER  
TOPICAL KATHARINASTOEGER 1-2001-00573  
LOCAL PETRA ffr/BER  
ANESTHETICS  
USING A  
PATCH

301717-117004 EPICEPT, INC. 8-Mar-01

Philippines  
Filed Wait Exam

Attorneys: ILENE B. TANNEN PETER G. THURLOW

---

010071-0005-149 EPICEPT CORPORATION INTRADERMAL  
PENETRATION  
AGENTS FOR WILFRIED FISCHER  
TOPICAL KATHARINASTOEGER PV2002-3030  
LOCAL PETRA ffr/BER  
ANESTHETICS  
USING A  
PATCH

301717-149004 EPICEPT, INC.  
Czech Republic  
Pending

Attorneys: ILENE B. TANNEN PETER G. THURLOW

---

010071-0005-158 EPICEPT CORPORATION  
INTRADERMAL  
PENETRATION  
AGENTS FOR WILFRIED FISCHER  
TOPICAL KATHARINASTOEGER 151671 151671  
LOCAL PETRA ffr/BER  
ANESTHETICS  
USING A  
PATCH

301717-158004 EPICEPT, INC. May 18, 2010  
Israel  
Registered

Attorneys: ILENE B. TANNEN PETER G. THURLOW

---

010071-0005-187 EPICEPT CORPORATION  
INTRADERMAL  
PENETRATION  
AGENTS FOR WILFRIED FISCHER  
TOPICAL KATHARINASTOEGER 10-2002-7011879 10-0764156  
LOCAL PETRA ffr/BER  
ANESTHETICS  
USING A  
PATCH

301717-187004 EPICEPT, INC. 28-Sep-07  
Republic of Korea  
Registered

Attorneys: ILENE B. TANNEN PETER G. THURLOW

---

010071-0005-228 EPICEPT CORPORATION  
INTRADERMAL  
PENETRATION  
AGENTS FOR WILFRIED FISCHER  
TOPICAL KATHARINASTOEGER PCT:USO 1107060  
LOCAL PETRA ffr/BER  
ANESTHETICS  
USING A  
PATCH

301717-228004 EPICEPT, INC. 6-Mar-01  
Patent Cooperation Treaty  
Completed

Attorneys: ILENE B. TANNEN PETER G. THURLOW

---

010071-0005-999	EPICEPT CORPORATION	INTRADERMAL PENETRATION AGENTS FOR TOPICAL LOCAL ANESTHETICA ADMINISTRATION	WILFRIED FISCHER KATHARINASTOEGER 09/523,652 PETRA HUBER		6,455,066
301717-999004	EPICEPT CORPORATION			10-Mar-00	24-Sep-02
United States of America					
Registered					
Attorneys:			ILENE B. TANNEN PETER G. THURLOW		

---

010071-0010-012	EPICEPT CORPORATION	METHODS AND COMPOSITION FOR TREATING PAIN OF THE MUCOUS MEMBRANE	ROBERT O. WILLIAMS FENGZHANG 2002-504977		
301717-012009	EPICEPT CORPORATION		JOHN J. KOLENG GAVRIL W. PASTERNAK YURI A. KOLESNIKOV	26-Jun-01	
Japan					
Pending					
Attorneys:			ILENE B. TANNEN PETER G. THURLOW		

---

010071-0010-158	EPICEPT CORPORATION	METHODS AND COMPOSITION FOR TREATING PAIN OF THE MUCOUS MEMBRANE	ROBERT O. WILLIAMS FENGZHANG 159656		
301717-158009	EPICEPT CORPORATION		JOHN J. KOLENG GAVRIL W. PASTERNAK YURI A. KOLESNIKOV		
Israel					
Filed Wait Exam					
Attorneys:			ILENE B. TANNEN PETER G. THURLOW		

---

010071-0010-227	EPICEPT CORPORATION	METHODS AND COMPOSITION FOR TREATING PAIN OF THE MUCOUS MEMBRANE	ROBERT O. WILLIAMS FENGZHANG 1948733.9		1296650
301717-227009	EPICEPT CORPORATION		JOHN J. KOLENG GAVRIL W. PASTERNAK YURI A. KOLESNIKOV	26-Jun-01	2-Mar-05
European Patent Office					
EP Granted					

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

010071-0010-228	EPICEPT CORPORATION	METHODS AND COMPOSITION S FOR TREATING PAIN OF THE MUCOUSMEMB RANE	ROBERT O. WILLIAMS FENGZHANG	PCT/US01/20322	
301717-228009	EPICEPT CORPORATION		JOHN J. KOLENG GAVRIL W. PASTERNAK YURI A. KOLESNIKOV		26-Jun-01

Patent Cooperation Treaty  
Completed

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

010071-0016-001	EPICEPT CORPORATION	TOPICAL COMPOSITION S AND METHODS FOR TREATING PAIN	ROBERT O. WILLIAMS FENGZHANG		2,457,780	2,457,780
301717-001015	EPICEPT CORPORATION				14-Aug-02	26-Oct-10

Canada  
Registered

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

010071-0016-007	EPICEPT CORPORATION	TOPICAL COMPOSITION S AND METHODS FOR TREATING PAIN	ROBERT O. WILLIAMS FENGZHANG		2002335635	2002335635
301717-007015	EPICEPT CORPORATION				14-Aug-02	18-Sep-08

Australia  
Registered

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

010071-0016-008	EPICEPT CORPORATION	TOPICAL COMPOSITION S AND METHODS FOR TREATING PAIN	ROBERT O. WILLIAMS FENGZHANG		531547	531547
301717-008015	EPICEPT CORPORATION				14-Aug-02	December 14, 2006

New Zealand  
Registered

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

010071-0016-009	EPICEPT CORPORATION	TOPICAL COMP	ROBERT O. WILLIAMS FEN	P A: a 12004 / 00 135.9		255023
301717-009015	EPICEPT CORPORATION				14-Aug-02	February 29, 2006

Mexico  
Registered

Attorneys: ILENE B. TANNEN THOMAS E. FRIEBEL PETER G. THURLOW

---

010071-0016-010 EPICEPT CORPORATION TOPICAL COMP. ROBERT O. WILLIAMS FEN 1813-2002 45.5  
301717-010015 EPICEPT CORPORATION 12-Aug-02 8-Jul-09

Chile  
Registered

Attorneys: ILENE B. TANNEN PETER G. THURLOW

---

010071-0016-023 EPICEPT CORPORATION TOPICAL COMP. ROBERT O. WILLIAMS FEN 6109763 HKI089364  
301717-023015 EPICEPT CORPORATION 14-Aug-02 5-Feb-10

Hong Kong  
Registered

Attorneys: ILENE B. TANNEN PETER G. THURLOW

---

010071-0016-025 EPICEPT CORPORATION TOPICAL  
COMPOSITION  
SAND ROBERT O. WILLIAMS 2002-001562  
METHODS FOR FENGZHANG  
TREATING  
PAIN  
301717-025015 EPICEPT CORPORATION 15-Aug-02

Venezuela  
Pending

Attorneys: ILENE B. TANNEN PETER G. THURLOW

---

010071-0016-036 EPICEPT CORPORATION TOPICAL  
COMPOSITION  
SAND ROBERT O. WILLIAMS P020103069  
METHODS FOR FENGZHANG  
TREATING  
PAIN  
301717-036015 EPICEPT CORPORATION 14-Aug-02

Argentina  
Pending

Attorneys: ILENE B. TANNEN PETER G. THURLOW

---

010071-0016-146 EPICEPT CORPORATION TOPICAL  
COMPOSITION  
SAND ROBERT O. WILLIAMS 2820112.4 ZL02820112.4  
METHODS FOR FENGZHANG  
TREATING  
PAIN  
301717-146015 EPICEPT CORPORATION 14-Aug-02 10-Jun-09

China  
Registered

Attorneys: ILENE B. TANNEN PETER G. THURLOW

---

010071-0016-158 EPICEPT CORPORATION TOPICAL COMP ROBERT O. WILLIAMS FEN 160388 160388  
301717-158015 EPICEPT CORPORATION May 18,2010

Israel  
Registered

Attorneys: ILENE B. TANNEN PETER G. THURLOW

---

010071-0016-227 EPICEPT CORPORATION TOPICAL  
COMPOSITION  
SAND ROBERT O. WILLIAMS 2770398.2  
METHODS FOR FENGZHANG  
TREATING  
PAIN

301717-227015 EPICEPT CORPORATION 14-Aug-02

European Patent Office  
Pending

Attorneys: ILENE B. TANNEN PETER G. THURLOW

---

010071-0016-228 EPICEPT CORPORATION TOPICAL  
COMPOSITION  
SAND ROBERT O. WILLIAMS PCT/US02/25871  
METHODS FOR FENGZHANG  
TREATING  
PAIN

301717-228015 EPICEPT CORPORATION 14-Aug-02

Patent Cooperation Treaty  
Completed

Attorneys: ILENE B. TANNEN PETER G. THURLOW CELEMORRIS

---

010071-0016-999 EPICEPT CORPORATION TOPICAL  
COMPOSITION  
SAND ROBERT O. WILLIAMS 91,931,293 6,638,981  
METHODS FOR FENGZHANG  
TREATING  
PAIN

301717-999015 EPICEPT CORPORATION 17-Aug-01 28-Oct-03

United States of America  
Registered

Attorneys: ILENE B. TANNEN PETER G. THURLOW

---

010071-0018-228 EPICEPT CORPORATION STERILE,  
BREATHABLE  
PATCH FOR PAUL MASON PCT/US02/33195  
TREATING  
WOUND PAIN

301717-228017 EPICEPT CORPORATION 17-Oct-02

Patent Cooperation Treaty  
Completed

Attorneys: ILENE B. TANNEN PETER G. THURLOW CELEMORRIS

---

010071-0026-999	EPICEPT CORPORATION	METHODS AND COMPOSITION S FOR TREATING PAIN OF THE MUCOUSMEMB RANE	ROBERT O. WILLIAMS FENGZHANG	101,172,455	6,509,028
301717-999025			JOHN J. KOLENG GAVRIL W. PASTERNAK YURI A. KOLESNIKOV	17-Jun-02	21-Jan-03
United States of America					
Registered					
Attorneys:		ILENE B. TANNEN ILENE B. TANNEN			

---

010071-0027-999	EPICEPT CORPORATION	INTRADERMAL PENETRATION AGENTS FOR TOPICAL LOCAL ANESTHETICA ADMINISTRA TION	WILFRIED FISCHER PETRA HUBER PAUL MASON	10/201,901	6,746,689
301717-999026	EPICEPT CORPORATION			10-Mar-00	8-Jun-04
United States of America					
Registered					
Attorneys:		ILENE B. TANNEN PETER G. THURLOW			

---

010071-0028-999	EPICEPT CORPORATION	PROCESS FOR THE PREPARATION JOHN A. FLORES	KENTON L. CROWLEY	08/866,770	5,817,699
301717-999027	EPICEPT CORPORATION	OF KETAMINE OINTMENT		May 30,1997	6-Oct-98
United States of America					
Registered					
Attorneys:		ILENE B. TANNEN PETER G. THURLOW			

---

010071-0048-012	EPICEPT CORPORATION	METHODS AND COMPOSITION S FOR TREATING PAIN OF THE MUCOUS MEMBRANE	ROBERT O. WILLIAMS FENGZHANG	2008-163375	
301717-012050	EPICEPT CORPORATION		JOHN J. KOLENG GAVRIL W. PASTERNAK YURI A. KOLESNIKOV	23-Jun-08	
Japan					
Pending					
Attorneys:		ILENE B. TANNEN PETER G. THURLOW			

---

010071-0048-023	EPICEPT CORPORATION	METHODS AND COMPOSITION SFOR TREATING PAIN OF THE MUCOUS MEMBRANE	ROBERT O. WILLIAMS FENGZHANG	5110883.4
301717-023050	EPICEPT CORPORATION		JOHN J. KOLENG GAVRIL W. PASTERNAK YURI A. KOLESNIKOV	28-Feb-05
Hong Kong Filed Wait Exam				
	Attorneys:		ILENE B. TANNEN PETER G. THURLOW	

---

010071-0051-999	EPICEPT CORPORATION	KETAMINE AND N-BUTYL P-AMINOBEZO ATE (sic) IN PLO		09:350.062	6,017.961
United States of America Registered	EPICEPT CORPORATION			8-Jul-99	25-Jan-00
	Attorneys:		ILENE B. TANNEN PETER G. THURLOW		

---

010071-0053-009	EPICEPT CORPORATION	TOPICAL COMPOSITION S AND METHODS FOR TREATING PAIN	ROBERT O. WILLIAMS FENGZHANG	Pat 12007/013047	
301717-009054	EPICEPT CORPORATION			October 19, 2007	
Mexico Pending					
	Attorneys:		ILENE B. TANNEN PETER G. THURLOW		

---



**EXHIBIT C**

Trademarks

[See Attached]

MAXIM PHARMACEUTICALS, INC. / EPICEPT CORPORATION

TRADEMARK STATUS REPORTS

Updated: April 26, 2011

MAXIM PHARMACEUTICALS, INC. - U.S. TRADEMARK APPLICATION REGISTRATIONS:

MARK	KMOB REF. NO. (MAXIM)	CLASS: GOODS/SERVICES	APP.NO./ APP.DATE	REG. NO./ REG. DATE	STATUS/ COMMENTS
CEPLENE	157T	5: Pharmaceuticals, namely, compositions for the treatment of cancer	76/138212 9/29/2000	2967403 7/12/2005	REGISTERED Renewal due 07/12/15

CEPLENE	221T	5: Pharmaceuticals, namely, compositions for the treatment of cancer	85/021009 4/22/2010		PENDING NOA issued 11/16/10 SOU/1 <sup>st</sup> due 5/15/11
VONTIV	156T	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	76/138211 9/29/2000	3252103 6/12/2007	REGISTERED Section 8 & 15 due 06/12/14 Renewal due 06/12/17

MAXIM PHARMACEUTICALS, INC. - FOREIGN TRADEMARK REGISTRATIONS

MARK	COUNTRY	KMOB REF. NO. (MAXIM)	CLASS: GOODS/SERVICES	APP.NO./ APP.DATE	REG. NO./ REG. DATE	STATUS/ COMMENTS
CEPLENE	Australia	157WAU	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	858297 11/23/00	858297 5/17/2001	REGISTERED Renewal due 11/23/20
CEPLENE	Canada	157WCA	5: Pharmaceuticals, namely compositions for the treatment of cancer	1078344 10/12/2000	TMA687350 5/9/2007	REGISTERED Renewal due 05/09/22
CEPLENE	China	157WCN	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	2001045526 3/28/2001	1760656 5/7/2002	REGISTERED Renewal due 05/07/12
CEPLENE	European Community	157WEC	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	1965656 11/22/00	1965656 08/22/02	REGISTERED Renewal due 11/22/20
CEPLENE	Iceland	157WIS	5: Pharmaceuticals	2516/2003 10/6/2003	30/2004 01/10/04	REGISTERED Renewal due 01/10/14

CEPLENE	Israel	157WIL	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	144206 11126/00	144206 2/5/2002	REGISTERED Renewal due 11/26/21
CEPLENE	Japan	157WJP	5: Composed pharmaceuticals for treatment of cancer; Composed pharmaceuticals for treatment of infectious disease; other pharmaceuticals	2001-029763 3/30/2001	4671668 5/16/2003	REGISTERED Renewal due 05/16/13
CEPLENE	Liechtenstein	157WLI	5: Pharmaceuticals	13015 10/8/2003	13015 01/13/04	REGISTERED Renewal due 11/26/21
CEPLENE	New Zealand	157WNZ	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	627694 9/29/2000	627694 5/24/2001	REGISTERED Renewal due 09/29/17
CEPLENE	Norway	157WNO	5: Pharmaceutical preparations	200309400 10/10/03	224104 9/1/2004	REGISTERED Renewal due 09/01/14
CEPLENE	Switzerland	157WCH	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	13973/2000 11/23/00	483420 4/4/2001	REGISTERED Renewal due 11/23/20
VONTIV	Australia	156WAU	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	858080 11/22/00	858080 5/17/2001	REGISTERED Renewal due 11/22/20
VONTIV	Canada	156WCA	5: Pharmaceuticals, namely compositions for the treatment of cancer and viral hepatitis	1078345 10/12/2000	TMA727471 10/30/08	REGISTERED Renewal due 10/30/23

VONTIV	China	156WCN	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	2001045525  3/28/2001	1760655  5/7/2002	REGISTERED  Renewal due 05/07/12
VONTIV	European Community	156WEC	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	1966977  11/22/00	1966977  5/23/2002	REGISTERED  Renewal due 11/22/20
VONTIV	Japan	156WJP	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	2001-027100  03/26/01	4503151  08/31/01	REGISTERED  Renewal due 08/31/11
VONTIV	Switzerland	156WCH	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	13972/2000  11/23/00	483419  4/4/2001	REGISTERED  Renewal due 11/23/20

EPICEPT CORPORATION - U.S. TRADEMARK APPLICATIONS

MARK	KMOB  REF. NO. (EPCPT*)	CLASS: GOODS SERVICES	APP. NO. /  APP. DATE	REG. NO. /  REG. DATE	STATUS /  COMMENTS
AMIKET	001T	5: Topical analgesics			UNFILED
CROLIBULIN	MAXIM.220T	5: Pharmaceutical preparation for the treatment of cancer	85/009435  4/8/2010		PENDING - TO BE  ABANDONED NOA issued 10/26/10

DISCLAIMER

To the best of our knowledge, the information contained in this Status Report is accurate. This Status Report is not to be used or relied upon for any purpose other than your general information. The Status Report contains confidential material and is protected by the attorney-client privilege.

111 28254/PJP/0426 11

**EXHIBIT D**

Mask Works

None.